New pill combo aims to slow kidney disease
NCT ID NCT06221059
First seen Dec 02, 2025 · Last updated May 22, 2026 · Updated 21 times
Summary
This study tested two experimental drugs, HRS-1780 and henagliflozin, in 181 adults with chronic kidney disease. The goal was to see if these drugs could reduce protein in the urine, a sign of kidney damage, over 13 weeks. Participants were already on standard blood pressure medications. The results will help determine if these drugs can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, 210002, China
Conditions
Explore the condition pages connected to this study.